Effect of a single IV infusion of zoledronic acid on bone turnover markers versus oral risedronate in patients with glucocorticoid-induced osteoporosis

被引：0
|
作者：
Sambrook, P.
Devogelaer, J.
Reginster, J.
Saag, K.
Roux, C.
Lau, C.
Papanastasiou, P.
Schoenborn-Kellenberger, O.
Maylandt, K.
Fashola, T.
Mesenbrink, P.
Reid, D.
机构：
[1] Univ Sydney, Sydney, NSW 2006, Australia
[2] Catholic Univ Louvain, B-1200 Brussels, Belgium
[3] Univ Liege, Liege, Belgium
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Paris Descartes Univ, Paris, France
[6] Univ Dundee, Dundee, Scotland
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Univ Aberdeen, Aberdeen, Scotland
来源：
BONE | 2009年 / 44卷
关键词：
D O I：
10.1016/j.bone.2009.01.213
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
297
引用
收藏
页码：S94 / S95
页数：2
相关论文
共 50 条
  • [21] Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases
    Kim, Ji-Won
    Jung, Ju-Yang
    Kim, Hyoun-Ah
    Son, Heejun
    Suh, Chang-Hee
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1183) : 334 - 341
  • [22] Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
    Delmas, Pierre D.
    Vrijens, Bernard
    Eastell, Richard
    Roux, Christian
    Pols, Huibert A. P.
    Ringe, Johann D.
    Grauer, Andreas
    Cahall, David
    Watts, Nelson B.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (04): : 1296 - 1304
  • [23] Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
    Kim, Ji-Won
    Jung, Ju-Yang
    Kim, Hyoun-Ah
    Suh, Chang-Hee
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2577 - 2579
  • [24] Bone: Once-yearly zoledronic acid ameliorates glucocorticoid-induced bone loss
    Heath V.
    Nature Reviews Endocrinology, 2009, 5 (8) : 413 - 413
  • [25] Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
    Adachi, Jonathan
    Chines, Arkadi
    Huang, Shuang
    Saag, Kenneth
    Lems, Willem
    Geusens, Piet
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 916 - 919
  • [26] Effect of Zoledronic Acid (Single 5-mg Infusion) on Lumbar Spine Bone Mineral Density Versus Oral Risedronate (5 mg/day) Over 1 Year in Subgroups of Patients Receiving Glucocorticoid Therapy.
    Roux, C.
    Reid, D.
    Devogelaer, J.
    Saag, K.
    Lau, C.
    Reginster, J.
    Papanastasiou, P.
    Ferreira, A.
    Hartl, F.
    Fashola, T.
    Mesenbrink, P.
    Sambrook, P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S464 - S464
  • [27] RISEDRONATE COMBINED WITH MENATETRENONE MAY PREVENT GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS
    Yuko, Makita
    Hitoshi, Suzuki
    Masao, Kihara
    Hiromitsu, Fukuda
    Satoshi, Mano
    Takashi, Kobayashi
    Yasuhiko, Kanaguchi
    Tatsuya, Aoki
    Teruo, Hidaka
    Katsuhiko, Asanuma
    Yasuhiko, Tomino
    NEPHROLOGY, 2014, 19 : 171 - 171
  • [28] Bone effects of 17β-estradiol and dihydrotestosterone on bone turnover in a mouse model of glucocorticoid-induced osteoporosis
    Suominen, M. L.
    Rissanen, J. P.
    Morko, J.
    Ravanti, L.
    Kallio, P. J.
    Halleen, J. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S207 - S207
  • [29] Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Stephen M Krane
    Nature Clinical Practice Rheumatology, 2006, 2 (4): : 186 - 187
  • [30] Optimization of Bone Turnover Marker Measurements in a Mouse Model of Glucocorticoid-Induced Osteoporosis.
    Suominen, M. I.
    Rissanen, J. P.
    Peng, Z.
    Halleen, J. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S447 - S447
12345